Literature DB >> 20094027

Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage --- United States, October-December 2009.

.   

Abstract

In July 2009, the Advisory Committee on Immunization Practices (ACIP) issued recommendations for use of the influenza A (H1N1) 2009 monovalent vaccine. Recognizing that the vaccine supply would not be ample immediately but would grow over time, ACIP identified 1) initial target groups, consisting of approximately 160 million persons, and 2) a limited vaccine subset of the target groups, initially estimated at 42 million persons (and more recently estimated at 62 million persons), to receive first priority while the 2009 H1N1 vaccine supply was limited. ACIP recommended expanding vaccination to the rest of the population as vaccine supplies increased. To estimate 2009 H1N1 vaccination coverage to date for the 2009--10 influenza season, CDC analyzed results from the National 2009 H1N1 Flu Survey (NHFS) and the Behavioral Risk Factor Surveillance System (BRFSS) survey, conducted during December 27, 2009-January 2, 2010, and December 1-27, 2009, respectively. The results indicated that, as of January 2, an estimated 20.3% of the U.S. population (61 million persons) had been vaccinated, including 27.9% of persons in the initial target groups and 37.5% of those in the limited vaccine subset. An estimated 29.4% of U.S. children aged 6 months--18 years had been vaccinated. Now that an ample supply of 2009 H1N1 vaccine is available, efforts should continue to increase vaccination coverage among persons in the initial target groups and to offer vaccination to the rest of the U.S. population, including those aged >or=65 years.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20094027

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  36 in total

1.  Knowledge, attitudes, and behaviors of low-income women considered high priority for receiving the novel influenza A (H1N1) vaccine.

Authors:  Catherine A Boyd; Julie A Gazmararian; Winifred Wilkins Thompson
Journal:  Matern Child Health J       Date:  2013-07

2.  Planning for the control of pandemic influenza A (H1N1) in Los Angeles County and the United States.

Authors:  Dennis L Chao; Laura Matrajt; Nicole E Basta; Jonathan D Sugimoto; Brandon Dean; Dee Ann Bagwell; Brit Oiulfstad; M Elizabeth Halloran; Ira M Longini
Journal:  Am J Epidemiol       Date:  2011-03-22       Impact factor: 4.897

3.  Highlights of historical events leading to national surveillance of vaccination coverage in the United States.

Authors:  Philip J Smith; David Wood; Paul M Darden
Journal:  Public Health Rep       Date:  2011 Jul-Aug       Impact factor: 2.792

4.  Low acceptability of A/H1N1 pandemic vaccination in French adult population: did public health policy fuel public dissonance?

Authors:  Michaël Schwarzinger; Rémi Flicoteaux; Sébastien Cortarenoda; Yolande Obadia; Jean-Paul Moatti
Journal:  PLoS One       Date:  2010-04-16       Impact factor: 3.240

5.  The 2009 H1N1 pandemic influenza virus: what next?

Authors:  David M Morens; Jeffery K Taubenberger; Anthony S Fauci
Journal:  MBio       Date:  2010-09-28       Impact factor: 7.867

6.  Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses.

Authors:  Graeme E Price; Mark R Soboleski; Chia-Yun Lo; Julia A Misplon; Mary R Quirion; Katherine V Houser; Melissa B Pearce; Claudia Pappas; Terrence M Tumpey; Suzanne L Epstein
Journal:  PLoS One       Date:  2010-10-04       Impact factor: 3.240

7.  Optimizing vaccine allocation at different points in time during an epidemic.

Authors:  Laura Matrajt; Ira M Longini
Journal:  PLoS One       Date:  2010-11-11       Impact factor: 3.240

8.  Clinical outcomes of seasonal influenza and pandemic influenza A (H1N1) in pediatric inpatients.

Authors:  Pranita D Tamma; Alison E Turnbull; Aaron M Milstone; Sara E Cosgrove; Alexandra Valsamakis; Alicia Budd; Trish M Perl
Journal:  BMC Pediatr       Date:  2010-10-06       Impact factor: 2.125

9.  Identifying cost-effective dynamic policies to control epidemics.

Authors:  Reza Yaesoubi; Ted Cohen
Journal:  Stat Med       Date:  2016-07-24       Impact factor: 2.373

10.  Adverse events following pandemic influenza A (H1N1) 2009 monovalent and seasonal influenza vaccinations during the 2009-2010 season in the active component U.S. military and civilians aged 17-44years reported to the Vaccine Adverse Event Reporting System.

Authors:  Barbara H Bardenheier; Susan K Duderstadt; Renata J M Engler; Michael M McNeil
Journal:  Vaccine       Date:  2016-07-19       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.